On Tuesday, June 16th, LF Capital Acquisition Corp. (LFAC), held their shareholder vote to extend the SPAC’s maturity date by three months from June 22nd to September 22nd, to give them more time to find a target and close a deal. LFAC released their extension vote results today, showing only 13.5% of shareholders (2,089,939 out of 15,525,000) opted to redeem, bringing the cash in trust value down to an estimated $141.7 million. A good result.
For the remaining 13,435,061 public shares, management is contributing $0.03 per share to the trust for each of the next three months.
Of the 21 SPAC’s that are still searching or announced and trying to close their combinations, and have held an extension vote, 51.9% of public shares have opted to redeem, on average.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...